The role of IL-6, ferritin, and coagulopathy in Covid-19 clinical progression

Author:

Harahap Alvin TagorORCID,Irawan Cosphiadi,Susilo Adityo,Harimurti Kuntjoro,Gathmyr Dewi,Shatri HamzahORCID,Lubis Anna Mira,Nainggolan Leonard,Abdullah Murdani

Abstract

Background  In Covid-19 infection, the release of pro-inflammatory mediators in the setting of cytokine storm, primarily interleukin-6 (IL-6), has been hypothesized to induce pulmonary intravascular thrombosis and eventually systemic coagulopathy. However, the relationship between IL-6 and coagulopathy remains unclear in Covid-19 progression. We aimed to investigate the correlation of IL-6 with D-dimer, fibrinogen, prothrombin time (PT), and ferritin. Furthermore, we also analysed the changes of those parameters in relation with progression of Covid-19 disease. Methods  A prospective cohort study was conducted in moderate and severe Covid-19 patients from June 2020 to January 2021. A serial evaluation of IL-6, D-dimer, fibrinogen, ferritin, and PT was performed and correlated with the patient's condition at admission and on the 14th day. The outcomes (improvement, worsening, or discharged patients) were recorded during the study. Results  Of 374 patients, 73 study subjects (61 severe and 12 moderate Covid-19) were included in this study. A total of 35 out of 61 severe illness and one out of 12 moderate illness subjects had experienced worsening. Spearman-rank correlation of IL-6 with with ferritin, D-dimer, fibrinogen, and PT was 0.08 ( p=0.5), −0.13 ( p=0.27), 0.01 ( p=0.91), and 0.03 ( p=0.77), respectively. In ROC analysis, D-dimer (74,77%) and IL-6 (71,32%) were the highest among other variables (>60%). Conclusions  In Covid-19 patients, there was a correlation between elevated IL-6 and D-dimer levels with clinical deterioration. There was no correlation between elevated IL-6 levels with ferritin, D-dimer, fibrinogen, and PT levels. In conclusion, changes in IL-6 and D-dimer can be independent predictor of disease progression in moderate and severe Covid-19 patients.

Publisher

F1000 Research Ltd

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3